The only thing that is really new in the half yearly is the following comment on currently expected timing for securing a clinical partner in Japan for Progenza:
"We have advanced our discussions and due diligence on securing our first clinical partner for Progenza in Japan. We are working closely with AGC in relation to securing a licensing partner and expect to make an announcement about this by the end of the financial year. "
zeno9
RGS Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
